YIDU TECH (02158) Reports RMB61.31 Million Net Profit for Interim of Fiscal 2027, With Profitability Continuing to Improve

date
18:34 22/11/2026
avatar
GMT Eight
YIDU TECH (02158) released its interim results report for fiscal year 2027 on November 22, according to Zhitong Finance APP. For the six months ended September 30, 2026, the company achieved year-on-year revenue growth of 5.3%, with net profit of approximately RMB61.31 million for the period. This not only extends the full-year profitability trend of the previous fiscal year but also reaches nearly 80% of last year's full-year profit.
On November 22, the Hong Kong-listed company YIDU TECH (02158) released its interim results report for fiscal year 2027. For the six months ended September 30, 2026, the company achieved revenue growth of 5.3% year-on-year, with net profit of approximately RMB61.31 million for the period. This not only continued the profitable operating trend of the previous full fiscal year, but also reached nearly 80% of last year's full-year profit. Improvement in profit quality became a highlight of this period's results. During the reporting period, the company continued to optimize its cost structure, with operating expenses as a percentage of revenue declining from 61% to 51.8%, further demonstrating the effectiveness of expense control. During the reporting period, YIDU TECH's three major business segments developed steadily. Among them, revenue from life sciences solutions increased 9.1% year-on-year, revenue from health management platforms and solutions increased 4.2% year-on-year, and revenue from big data platforms and solutions remained basically stable. At present, the company has cumulatively served 141 top Chinese hospitals and 53 regulatory agencies and policymakers; 16 of the top 20 multinational pharmaceutical companies are YIDU TECH customers; in the health management field, it has served as the main operating platform for Beijing Huihui Health Insurance for six consecutive years and as the main operating platform for Shenzhen Huimin Insurance for four consecutive years. As medical AI moves from technical validation to large-scale application, industry competition is gradually shifting from model capabilities to application results and commercial value in real-world scenarios. YIDU TECH continues to use YiduCore as its core to promote deep integration of data, algorithms, and medical business scenarios. The profit growth and expense efficiency improvements reflected in this interim results also provide support for the company's next stage of business expansion and large-scale development.